Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2018-07-24 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
Issue of Equity
Share Issue/Capital Change Classification · 98% confidence The document is identified by the 'RNS Number' header and explicitly states it is provided by 'RNS, the news service of the London Stock Exchange'. The content details the 'Issue of Equity' (issuance of 3,184,620 new ordinary shares) and the subsequent application for admission to trading on AIM, along with the resulting total number of voting rights. This is a specific corporate action announcement related to share capital changes. While it relates to share capital, the primary nature of the filing is a regulatory news service announcement. Since the document is short (3944 chars) and is a direct announcement of an event rather than a comprehensive report, and it is explicitly labeled as an RNS filing, the most appropriate code is RNS, as it is a general regulatory announcement that doesn't fit the more specific 'SHA' (Share Issue/Capital Change) which usually implies a more formal prospectus or detailed filing, although SHA is a close second. Given the RNS header and context, RNS is the best fit for this type of immediate market disclosure.
2018-07-24 English
Scancell exercises TriGrid commercial option
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated July 18, 2018. It announces a specific corporate action: Scancell exercising a commercial option for a license related to its SCIB1 vaccine and an upcoming clinical study. The text explicitly states, 'This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).' and concludes with information about RNS, the news service of the London Stock Exchange, which acts as a Primary Information Provider. This structure strongly indicates a regulatory news service announcement. Since the content is a specific corporate update (licensing/clinical trial progress) that doesn't fit the highly specific categories like DIV, DIRS, or ER, the most appropriate general regulatory filing category is RNS (Regulatory Filings), which serves as the fallback for miscellaneous regulatory announcements.
2018-07-18 English
Grant of European patent for Moditope platform
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated May 23, 2018. The content is a brief announcement from Scancell Holdings Plc regarding the grant of a European patent for its Moditope® immunotherapy platform. It is short, provides key highlights (patent grant, territories covered), and concludes with contact information referencing 'RNS, the news service of the London Stock Exchange' and the FCA. This structure strongly indicates a general regulatory news service announcement rather than a comprehensive report (like 10-K or IR) or a specific financial event (like ER or DIV). Since it is a general regulatory announcement that doesn't fit the more specific categories (like DIRS, MANG, or CAP), the most appropriate classification is Regulatory Filings (RNS). The document length (4126 chars) is also consistent with a brief RNS announcement.
2018-05-23 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is explicitly labeled with 'RNS Number : 8416N' and contains the header 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in major shareholdings, which falls under regulatory disclosure requirements. The presence of 'RNS Number' and the nature of the content (reporting changes in voting rights/share ownership by Legal & General Group Plc) strongly indicate a regulatory filing related to share ownership thresholds. This aligns best with the 'Major Shareholding Notification' category (MRQ). Although RNS is a general category, MRQ is more specific for this type of disclosure.
2018-05-11 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly labeled with "RNS Number : 4945N" and contains the header "TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES". This format is standard for regulatory notifications concerning changes in major shareholdings, which aligns directly with the definition for Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the classification. The document details the acquisition/disposal of voting rights, crossing a threshold (13%), and names the parties involved, confirming it is a major shareholder disclosure.
2018-05-09 English
Result of the Open Offer and PDMR Shareholdings
Share Issue/Capital Change Classification · 99% confidence The document begins with an 'RNS Number' and is dated May 8, 2018. It discusses the 'Result of the Open Offer' (a capital raising event) and provides detailed tables regarding 'PDMR shareholdings' (transactions by persons discharging managerial responsibilities). The structure, content (reporting insider trades and capital raise results), and explicit mention of 'NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES' strongly indicate this is a regulatory disclosure. Since it reports on director share transactions following a capital event, it fits the description of insider trading/director dealing (DIRS) or a general regulatory announcement (RNS). Given the primary focus on the results of the Open Offer (a capital/financing update) and the mandatory disclosure of PDMR transactions resulting from it, it is a hybrid. However, the explicit inclusion of the standardized PDMR notification tables points strongly towards Director's Dealing (DIRS) being a key component, or RNS as the general regulatory filing. Since the document also details the results of a capital raise and subsequent director subscriptions, it relates to both CAP and DIRS. The presence of the RNS header and the nature of mandatory disclosure makes RNS a strong candidate, but DIRS specifically covers the PDMR transaction reporting. Since the document is a formal announcement of results and insider trades, and not just a short notice pointing to a report, it is a specific filing type. The combination of capital raise results and mandatory PDMR disclosure makes it a specific regulatory filing. Given the explicit PDMR tables, DIRS is highly relevant, but RNS is the general category for these LSE disclosures. Reviewing the definitions, DIRS is for 'Report of personal share transactions by company directors and executives (insider trades)'. This document contains exactly that, alongside the capital raise results. Since the PDMR section is highly structured and detailed, DIRS is a very strong fit. However, the document is fundamentally an RNS announcement reporting on the completion of a capital raise and associated insider transactions. RNS is the most appropriate general regulatory filing code when multiple specific events are announced under the RNS system, especially when it's not a core financial statement (10-K, IR) or a specific proxy/remuneration document. I will classify it as RNS as it is a general regulatory announcement disseminated via the RNS system covering multiple aspects (capital raise result + PDMR).
2018-05-08 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.